PPARγ Pro12Ala Polymorphism in HIV-1-Infected Patients with HAARTRelated Lipodystrophy
María Saumoy(Bellvitge University Hospital), Francesc Vidal(Institut de Recerca Biomèdica Catalunya Sud), Montserrat Broch(Hospital Universitari Joan XXIII de Tarragona), Merce Miranda(Hospital Universitário da Universidade de São Paulo), Carlos Alonso‐Villaverde(Institut de Recerca Biomèdica Catalunya Sud), Cristóbal Richart(Universitat Rovira i Virgili), Matilde R. Chacón(Institut de Recerca Biomèdica Catalunya Sud), Teresa Auguet(Institut de Recerca Biomèdica Catalunya Sud), Peré Domingo(Hospital de Sant Pau), Consuelo Viladés(Hospital Universitario Fundación Jiménez Díaz), Miguel López-Dupla, Gerard Aragonès, Sergi Veloso, Montserrat Olona(Institut de Recerca Biomèdica Catalunya Sud), Joaquim Peraire(Instituto de Salud Carlos III), Carmen Aguilar(Instituto de Salud Carlos III), Joan-Josep Sirvent(Institut de Recerca Biomèdica Catalunya Sud), Joan Vendrell(Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas)
Cited by 13
Related Papers
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
|The Lancet Infectious Diseases|2015|143
Relationship between current level of immunodeficiency and non‐acquired immunodeficiency syndrome‐defining malignancies
|Cancer|2010|141
Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study
|The Lancet HIV|2021|110
Disruption of GIP/GIPR Axis in Human Adipose Tissue Is Linked to Obesity and Insulin Resistance
|The Journal of Clinical Endocrinology & Metabolism|2014|108
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial
|Clinical Infectious Diseases|2017|103